Blood test could personalize breast cancer therapy
NCT ID NCT07394218
First seen Feb 06, 2026 · Last updated May 01, 2026 · Updated 8 times
Summary
This study explores whether a blood test that tracks tumor DNA (ctDNA) can help doctors choose the best treatment for people with HER2-negative metastatic breast cancer. About 122 participants will receive antibody-drug conjugate therapy, and those whose cancer does not worsen will be assigned to different treatments based on changes in their ctDNA levels. The goal is to see if this approach improves outcomes without requiring lifelong medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CTDNA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.